Lasmiditan is a new oral medication for treatment of acute migraine. It was approved by the U.S. Food and Drug Administration in October 2019 and is marketed under the brand name Reyvow (Eli Lilly and Company, Indianapolis, IN). It is the first of its kind in a new drug class called ditans. Lasmiditan has been studied as monotherapy for acute migraine treatment and as an abortive therapy for adults taking chronic migraine preventive medication. Lasmiditan may be an option for individuals who have had no relief with triptans or other acute migraine treatment agents or who are unable to use other migraine treatments because of contraindications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.nwh.2020.05.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Knowledge, attitudes, and practices of migraine management among primary health care physicians in Al-Madinah Al-Munawarah.
J Med Life
November 2024
College of Medicine and Surgery, Taibah University, Madinah, Kingdom of Saudi Arabia.
Migraine is a burdensome primary headache disorder with a global prevalence ranging from 15-18%. Our study aimed to assess the knowledge among primary healthcare physicians regarding migraine and evaluate whether their management practices align with current advances. This descriptive cross-sectional study included 212 primary healthcare physicians working in Al-Madinah Al-Munawarah, Kingdom of Saudi Arabia.
View Article and Find Full Text PDFPhenotype of Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in Children.
J Clin Neurol
January 2025
Department of Pediatrics, Seoul National University Children's Hospital, Seoul, Korea.
Background And Purpose: To determine the clinical phenotypes, relapse timing, treatment responses, and outcomes of children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
Methods: We collected the demographic, clinical, laboratory, and radiological data of patients aged <18 years who had been diagnosed with MOGAD at Seoul National University Children's Hospital between January 2010 and January 2022; 100 were identified as positive for MOG antibodies, 43 of whom experienced relapse.
Results: The median age at onset was 7 years (range 2-16 years).
US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review.
Adv Ther
January 2025
Dent Neurologic Institute, 3980 Sheridan Dr., Amherst, NY, 14226, USA.
Introduction: Fremanezumab, a monoclonal antibody (mAb) targeting the calcitonin gene-related peptide (CGRP) pathway, and gepants, small molecule CGRP receptor antagonists, are both approved for the treatment of migraine or its symptoms. This study assessed effectiveness, tolerability, and migraine-related healthcare resource utilization (HCRU) after the addition of fremanezumab for preventive migraine treatment in patients using gepants for acute treatment.
Methods: Data were extracted during a retrospective chart review from electronic medical records from the Dent Neurologic Institute.
Structural Magnetic Resonance Imaging of Post-Traumatic Headache: A Systematic Review.
Curr Pain Headache Rep
January 2025
Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Valdemar Hansens Vej 5, Entrance 1A, 2600 Glostrup, Copenhagen, Denmark.
Purpose Of Review: To evaluate the available studies on structural magnetic resonance imaging (MRI) of post-traumatic headache (PTH).
Recent Findings: A systematic search of PubMed and Embase databases (from inception to February 1, 2024) identified nine relevant structural MRI studies. These studies included adult participants diagnosed with acute or persistent PTH in adherence with any edition of the International Classification of Headache Disorders.
Real-World Open-Label Experience with Rimegepant for the Acute Treatment of Migraine Attacks: A Multicenter Pilot Study.
Brain Sci
November 2024
Headache Outpatient Clinic, Neurology Department, Patras Agios Andreas General Hospital of Patras, 26335 Patras, Greece.
The present open-label multicenter pilot study sought to prospectively evaluate the efficacy and safety of rimegepant in treating migraine attacks. The primary endpoint was pain freedom at two hours post-dose, while the co-primary efficacy endpoints included a reduction in the headache intensity and freedom from the most bothersome symptoms (MBS) associated with migraine at the same time point. To test the potential efficacy of rimegepant, patients were asked to record in a questionnaire all the relevant changes with each migraine attack treated with rimegepant at two hours post-dose vs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!